Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00029328 |
Recruitment Status :
Completed
First Posted : January 11, 2002
Last Update Posted : March 25, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Respiratory Distress Syndrome, Adult Bronchiolitis Obliterans Pneumonia | Drug: etanercept | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 15 participants |
Allocation: | Non-Randomized |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation |
Study Start Date : | September 2001 |
Study Completion Date : | September 2003 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Months and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Diagnosis of acute idiopathic pneumonia syndrome (IPS) or sub-acute lung injury
- At least 1 year of age for IPS stratum
- At least 6 years of age for sub-acute lung injury stratum and able to perform formal pulmonary function testing
- At least 14 days since prior treatment with an investigational drug for graft-versus-host disease
- Previously treated with allogeneic stem cell or bone marrow transplantation for primary disease
Exclusion criteria:
- Documented evidence of active systemic or pulmonary infection
- Cardiogenic failure as cause of pulmonary dysfunction
- Known hypersensitivity to etanercept
- Currently receiving dialysis
- Currently receiving inotropic medications except dopamine
- Pregnant or nursing

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00029328
United States, Michigan | |
University of Michigan | |
Ann Arbor, Michigan, United States, 48109 |
Principal Investigator: | Kenneth Cooke, M.D. | University of Michigan, Ann Arbor, MI |
ClinicalTrials.gov Identifier: | NCT00029328 |
Other Study ID Numbers: |
FD-R-2020-01 UMCC-0078; FD-R-002020-01 |
First Posted: | January 11, 2002 Key Record Dates |
Last Update Posted: | March 25, 2015 |
Last Verified: | November 2001 |
TNFR-Fc fusion protein Stem Cell Transplantation Transplantation, Homologous Respiratory Function Tests |
Pneumonia Bronchiolitis Respiratory Distress Syndrome Respiratory Distress Syndrome, Newborn Bronchiolitis Obliterans Acute Lung Injury Respiratory Tract Infections Infections Lung Diseases Respiratory Tract Diseases Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases Bronchitis Bronchial Diseases |
Lung Diseases, Obstructive Lung Injury Etanercept Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Gastrointestinal Agents Immunosuppressive Agents Immunologic Factors |